RT @breastguide: Validation of the 21-gene test as a predictor of clinical response to neoadjuvant hormonal therapy for ER+, HER2-negative…
RT @breastguide: Validation of the 21-gene test as a predictor of clinical response to neoadjuvant hormonal therapy for ER+, HER2-negative…
Validation of the 21-gene test as a predictor of clinical response to neoadjuvant hormonal therapy for ER+, HER2-negative breast cancer: the TransNEOS study | SpringerLink https://t.co/NjBBdkKIWm
RT @kristinrojasmd: Getting heated in #MiamiBreast Cancer Conference #TumorBoard @Fontainebleau re: preoperative/#neoadjuvant endocrine the…
RT @kristinrojasmd: Getting heated in #MiamiBreast Cancer Conference #TumorBoard @Fontainebleau re: preoperative/#neoadjuvant endocrine the…
RT @kristinrojasmd: Getting heated in #MiamiBreast Cancer Conference #TumorBoard @Fontainebleau re: preoperative/#neoadjuvant endocrine the…
Getting heated in #MiamiBreast Cancer Conference #TumorBoard @Fontainebleau re: preoperative/#neoadjuvant endocrine therapy! Consider new evidence supporting #Oncotype to choose preop therapy for #BreastCancer patients? —> https://t.co/7ngXGQlhbP. @P